You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

TOPICAL NEPAFENAC AFTER INTRAVITREAL INJECTION: A Prospective Double-Masked Randomized Controlled Trial

Ulrich, J. Niklas MD

Retina:
doi: 10.1097/IAE.0b013e3182a0e611
Original Study
Abstract

Purpose: To evaluate if a single drop of nepafenac can reduce the ocular discomfort after intravitreal injections compared with placebo.

Methods: One hundred and twenty patients undergoing intravitreal injections of bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane Ultra) after the injection in a prospective, double-masked, randomized controlled design. Patients rated their pain levels from 0 to 3 (no pain, mild pain, moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure.

Results: Statistically significant reduction of postinjection pain with nepafenac was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6 [standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1 ± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15).

Conclusion: A single drop of nepafenac is effective in reducing discomfort after intravitreal injections.

In Brief

This prospective, double-masked, randomized controlled study suggests that a single drop of nepafenac is more effective in reducing discomfort after intravitreal injections than placebo (Systane Ultra).

Author Information

Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.

Reprint requests: J. Niklas Ulrich, MD, Department of Ophthalmology, University of North Carolina, 5151 Bioinformatics Building, CB 7040, Chapel Hill, NC 27599-7040; e-mail: jnulrich@med.unc.edu

Supported by an unrestricted grant from Research to Prevent Blindness.

The author has no conflicting interests to disclose.

© 2014 by Ophthalmic Communications Society, Inc.